Cutaneous lupus erthyematosus and anti-TNF-α therapy: A case report with review of the literature

Journal of Drugs in Dermatology

Volumn 9, Issue 10, 2010, Pages 1283-1287

  Levine, Danielle ^a   Switlyk, Stephen A ^b   Gottlieb, Alice ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CARBON DIOXIDE; CD44V ANTIGEN; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; PREDNISONE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CARBON DIOXIDE LASER; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; JUVENILE RHEUMATOID ARTHRITIS; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; MULTICENTER STUDY (TOPIC); PAIN; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; POLYARTHRITIS; PROTEIN EXPRESSION; PRURITUS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; DISCOID LUPUS ERYTHEMATOSUS; DRUG ANTAGONISM;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, DISCOID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78049522399     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Prescott K, Costner M, Cohen S, Kazi S. Tumor necrosis factor-alpha inhibitor associated ulcerative colitis. Am J Med Sci. 2007;333:137-139. (Pubitemid 47181611)
2. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumor necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol. 1996;35:1067-1074.
3. Le Hir M, Haas C, Marino M, Ryffel B. Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. Lab Invest. 1998;78:1625-1631. (Pubitemid 29022238)
4. Aringer M, Graninger WF, Steiner G, Smolen J. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open label study. Arthritis Rheum. 2004;50:3161-3169. (Pubitemid 39371992)
5. Fautrel B, Foltz V, Frances C, et al. Regression of subacute lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent. Arthritis Rheum. 2002;46:1408-1409.
6. Ramos-Casals M, Brito-Zerón P, Soto MJ, et al. Autoimmune diseases induced by TNF-α-targeted therapies. Best Pract & Res Clin Rheum. 2008;22:847-861.
7. De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: A French national survey. Arthritis Res Ther. 2005;7:R545-R551.
8. Mohan AK, Edwards ET, Cote TR, et al. Drug-induced systemic lupus erythematosus and TNF-α blockers. Lancet. 2002;360:646.
9. Sheth N, Greenblatt D, Patel S, Acland K. Adalimumab-induced cutaneous lupus. Clin Exp Dermatol. 2007;32:593-594.
10. Bleumink GS, Borg EJ, Ramselaar CG, Stricker BHC. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology. 2001;40:1317-1379.
11. Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003;48:1165-1166. (Pubitemid 36418265)
12. Richez C, Dumoulin C, Schaevereke T. Infliximab induced chilblain lupus in a patient with rheumatoid arthritis. J Rheumatol. 2005;32:760-761. (Pubitemid 40524717)
13. Benucci M, Li Gobbi F, Fossi F, et al. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol. 2005;11(1):47-49. (Pubitemid 40223880)
14. Schneider SW, Staender S, Schlüter B, et al. Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol. 2006;142:115-116. (Pubitemid 43107378)
15. Misery L, Perrot JL, Gentil-Perret A, et al. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol. 2002;146:331-344.
16. Sarzi-Puttini P, Ardizzone S, Manzionna G, et al. Infliximab-induced lupus in Crohn's disease: A case report. Dig Liver Dis. 2003;35(11):814-817. (Pubitemid 41070514)
17. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20(7):1400-1406. (Pubitemid 41430613)
18. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003;9:176-178. (Pubitemid 36592448)
19. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002;11(11):753-755. (Pubitemid 35408081)
20. Van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, et al. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology (Oxford). 2006;45:1317-1319. (Pubitemid 44542083)
21. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-α-induced systemic lupus syndrome. Clin Rheumatol. 2003;22:56-61.
22. Swale VJ, Perrett CM, Denton CP. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol. 2003;28:604-607. (Pubitemid 37430879)
23. Brion PH, Mittal-Henkel A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med. 1999;131:634. (Pubitemid 29494103)
24. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;16:359:579-80. (Pubitemid 34178442)
25. Stratigos AJ, Antoniou C, Stamathioudaki S, et al. Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol. 2004;29:150-153. (Pubitemid 38367198)
26. High W, Muldrow M, Fitzpatrick J. Cutaneous lupus erythematosus induced by infliximab. J Am Acad Dermatol. 2005;52:E5.
27. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor α agents. Semin Arthritis Rheum. 2008;37:381-387. (Pubitemid 351734520)
28. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med. 1999;130:47-486.
29. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor-α: Findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383-2390.
30. Vedove CD, Giglio MD, Schena D, Girolomoni G. Drug-induced lupus erythematosis. Arch Dermatol Res. 2009;301:99-105.
31. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanecerpt for rheumatoid arthritis. Ann Rheum Dis. 2002;61:1031-1032. (Pubitemid 35221697)
32. Aringer M, Steiner G, Graninger W, Smolen J. Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: Comment on the editorial by Pisetsky. Arthritis Rheum. 2001;44:1721-1722. (Pubitemid 32642240)
33. DeBandt M. Lessons for lupus from tumor necrosis factor blockade. Lupus. 2006;15:762-767.
34. Aringer M, Steiner G, Graninger W, et al. Effects of short-term Infliximab therapy on autoantibodies in systemic lupus erythematosus. An open label study. Arthritis Rheum. 2007;56:274-279. (Pubitemid 46106201)
35. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor: Findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383-2390.
36. Kocharla L, Mongey AB. Is the development of drug-related lupus a contraindication for switching from one TNF-α inhibitor to another? Lupus. 2009;18:169-171.
37. Ferraccioli G, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy. Ann Rheum Dis. 2002;61:358-361.
38. Ding C, Foote S, Jones G. B-cell-targeted therapy for systemic lupus erythematosus: An update. BioDrugs. 2008;22:239-249. (Pubitemid 351969831)